Latest News and Press Releases
Want to stay updated on the latest news?
-
LOS ANGELES, Dec. 15, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises MoonLake Immunotherapeutics, Inc., (“MoonLake” or the "Company") (NASDAQ: MLTX) investors of a class action on behalf of...
-
MoonLake Immunotherapeutics investors that lost money are encouraged to contact BG&G before the December 15, 2025 lead plaintiff deadline.
-
Investors who lost money in MLTX after its stock plunged 90% due to allegedly misleading financial statements are urged to contact Hagens Berman.
-
Important MoonLake Immunotherapeutics Securities Fraud Class Action Deadline is Approaching for Investors – Contact BFA Law before December 15
-
Investors who lost money in MoonLake after its stock plunged 90% due to allegedly misleading financial statements are urged to contact Hagens Berman.
-
MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm
-
MoonLake Immunotherapeutics Stock Dropped 90% after Drug Trial Results; Contact BFA Law about the Pending Securities Class Action
-
MoonLake Immunotherapeutics investors that lost money are encouraged to contact BG&G before the December 15, 2025 lead plaintiff deadline.
-
LOS ANGELES, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises MoonLake Immunotherapeutics, Inc., (“MoonLake” or the "Company") (NASDAQ: MLTX) investors of a class action on behalf of...
-
MoonLake Immunotherapeutics Hit with Securities Fraud Class Action after Drug Trial Results – Contact BFA Law if You Suffered Losses